JAZZ News and Press, Jazz Pharmaceuticals plc From 08/31/21

Jazz Pharmaceuticals Announces Health Canada Approval of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea Canada NewsWire DUBLIN , Aug. 31, 2021 /CNW/ - Jazz Pharmaceuticals plc (NASDAQ: JAZZ) toda...

Medical Marijuana Stocks In 2021 Are you looking for different ways to invest in top marijuana stocks in 2021? At the present time, many of the best cannabis stocks to invest in are trading near their lowest price points for the year. One area that shows more stability than vertically i...

Leading-edge AI and shopping technology combine to increase revenue opportunities and conversions of exclusive artist merchandise Campbell CA - ( NewMediaWire ) - August 24, 2021 - Friendable Inc. (OTC: FDBL) (the “Company”), a mobile technology and marketing company, is ple...

Jazz Pharmaceuticals (NASDAQ: JAZZ) is a cross between a pharmaceutical stock and a cannabis stock. In its earlier life, it was a pharmaceutical company that was chugging along and posting some good numbers. But after it acquired GW Pharmaceuticals earlier this year, that changed. N...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults Xywav is the first and only FDA-approved treatment for idiopathic hypersomnia Individualized Xywav dosing r...

Campbell CA - ( NewMediaWire ) - August 11, 2021 - Friendable Inc. (OTC: FDBL), a mobile technology and marketing company, is pleased to announce its two new video trailers, designed to showcase the Fan Pass Livestream platform and entice both artists and music fans around the world to sign ...

Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers $4 Million Research Collaboration to Explore New Treatment Options for Pediatric Solid Tumors or RAF, RAS Mutated Tumors PR Newswire LOS ANGELES , Aug. 10...

NetworkNewsWire Editorial Coverage New York, NY – August 5, 2021 – A leading cause of death in the United States for men and women of most racial and ethnic groups, heart disease is a pervasive health challenge that destroys lives. The Centers for Disea...

Avadel's once-nightly FT218 improves considerably over Xyrem's twice-nightly dosing. Jazz's recent lawsuit seems spurious, given how they lost to Amneal before. October PDUFA and current low prices make AVDL a compelling buy. For further details see: Avadel Pharmaceutica...

After the market closed on Tuesday, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced financial results for the second quarter of 2021 and affirmed non-GAAP adjusted financial guidance for 2021. Jazz also said that it plans to expand the use of GW Pharmaceutical’s drug ...